| 1994-07-01 |
July 1994: Established Sohiken Medical Science Laboratory, a limited company in Sakai City, Osaka Prefecture, with capital of 3,000,000 yen, aiming to develop biomarkers and bioevaluation systems useful for clinical drug development. |
| 1994-07 |
Our group, in July of the 6th year of Heisei (1994), established by our director Osamu Kajimoto, develops biomarkers and bioevaluation systems using them to establish new pharmaceuticals and functional foods. |
| 1994-07 |
Established Sogo Medical Science Research Institute Ltd. in Sakai City, Osaka Prefecture, with capital of 3 million yen, for the development of biomarkers and bioevaluation systems useful for clinical drug development. |
| 1994-07 |
In July of Heisei 6 (1994), our director Osamu Kajimoto established a new pharmaceutical and functional product development system through biomarker development and bio-evaluation system establishment. |
| 1996-06 |
June 1996: Moved headquarters to Chuo Ward, Osaka City. |
| 1996-06 |
Relocated headquarters to Chuo-ku, Osaka. Established Japan Clinical System Inc. (now a consolidated subsidiary) for the sale of functional foods and planning/sales of medical devices. |
| 2001-04 |
April 2001: Moved headquarters to Toyonaka City, Osaka Prefecture. |
| 2001-04 |
Relocated headquarters to Toyonaka City, Osaka Prefecture. |
| 2001-12 |
December 2001: Changed organization to Sohiken Co., Ltd. |
| 2001-12 |
Organizational change to Sogo Medical Science Research Institute Inc. |
| 2002-05 |
May 2002: Started business alliance with Sohiken Clinic. |
| 2002-05 |
Started business alliance with Sogo Clinic. |
| 2003-06 |
June 2003: Signed a research contract with Osaka City University for the development of food and drug products using new biomarkers and their functional analysis for fatigue and related conditions. |
| 2003-06 |
Signed a research consignment contract with Osaka City University for the development of fatigue-related food drugs using new biomarkers and their functional analysis. |
| 2003-07 |
July 2003: Opened Tokyo Branch in Minato-ku, Tokyo. |
| 2003-07 |
Opened a Tokyo branch in Minato Ward, Tokyo. |
| 2003-10 |
October 2003: Started fatigue quantification and anti-fatigue food drug development project. |
| 2003-10 |
Started a project for quantification of fatigue and development of anti-fatigue food medicines. |
| 2003-12 |
December 2003: Listed on the Mothers section of the Tokyo Stock Exchange. |
| 2003-12 |
Listed shares on the Mothers section of the Tokyo Stock Exchange. |
| 2005-12 |
December 2005: Established Virus Medical Science Research Institute Inc. (now a non-consolidated subsidiary) to commercialize fatigue biomarkers using viruses. |
| 2005-12 |
Established Virus Medical Science Research Institute Inc. (currently a non-consolidated subsidiary) for the commercialization of fatigue biomarkers using viruses. |
| 2006-01 |
January 2006: Established Evidence Lab Inc. (now a consolidated subsidiary) in joint venture with Hakuhodo Inc. for post-marketing surveys and marketing research of specified health foods, etc., through a website that disseminates information on specific health foods. |
| 2006-01 |
Established Evidence Lab Inc. (currently a consolidated subsidiary) in joint venture with Hakuhodo Inc. for the purpose of conducting post-marketing surveys and marketing research of health foods, etc., through a website that disseminates information about specified health foods. |
| 2006-07 |
July 2006: Acquired B.B. Laboratories Inc. and two other companies (now consolidated subsidiaries) to expand into the cosmetics business. |
| 2006-07 |
Acquired B.B. Laboratories Inc. and two other companies (currently consolidated subsidiaries) to expand into the cosmetics business. |
| 2007-01 |
January 2007: Transitioned to a holding company structure to improve group management efficiency and strengthen corporate governance. Established Sogo Medical Science Research Institute Inc. as a new company through a spin-off of business divisions, and changed the company name to Sogo Kenko Holdings Inc. |
| 2007-01 |
Transitioned to a holding company structure to improve group management efficiency and strengthen corporate governance. Established a new business division as a spin-off, and founded Sogo Medical Science Research Institute Inc. (currently a consolidated subsidiary) as a new company, with the company becoming a holding company and changing its trade name to Sogo Medical Science Research Institute Inc. |
| 2007-05 |
May 2007: Changed the trade name of Japan Clinical System Inc. to Japan Preventive Medicine Inc. to commercialize functional foods for medical institutions, and subscribed to the issuance of new shares through a shareholder allocation, making it a consolidated subsidiary. |
| 2007-05 |
Changed the trade name of Japan Clinical System Inc. to Japan Preventive Medicine Inc. to commercialize functional foods and other products for medical institutions, and subscribed for new shares issued through a shareholder allotment, making it a consolidated subsidiary. |
| 2008-02 |
February 2008: Relocated Tokyo Branch to Chiyoda-ku, Tokyo. |
| 2008-02 |
Relocated the Tokyo branch to Chiyoda Ward, Tokyo. |
| 2015-05 |
May 2015: Signed a business and capital alliance agreement with Chinese cosmetics company Beautyplus Holdings Hongkong Limited to build a cooperative relationship for cosmetics sales in the Chinese market. |
| 2015-05 |
Signed a business alliance and capital alliance agreement with Chinese cosmetics company Beautyplus Holdings Hongkong Limited to build a cooperative relationship for cosmetics sales in the Chinese market. |
| 2017-06 |
June 2017: Made NRL Pharma Inc., which develops and sells functional ingredients centered on lactoferrin, a consolidated subsidiary. |
| 2017-06 |
Made NRL Pharma Inc., which develops and sells functional ingredients centered on lactoferrin, a consolidated subsidiary. |
| 2019-02 |
February 2019: Signed a capital and business alliance agreement with Chinese distribution company Hangzhou Golong Holding Co., Ltd. to build a partnership for cosmetics and health supplement sales in China. |
| 2019-02 |
Signed a capital and business alliance agreement with Chinese distribution company Hangzhou Golong Holding Co., Ltd. to build a partnership for cosmetics sales and health supplement sales in the Chinese market. |
| 2022-04 |
April 2022: Transitioned from the Tokyo Stock Exchange Mothers to the Growth Market due to a review of market classification. |
| 2022-04 |
Moved from the Tokyo Stock Exchange Mothers market to the Growth market due to a review of market classification. |
